Eli Lilly reported annual revenue of $65.18 billion in 2025, a 44.70% increase over the prior year. The company's trailing twelve-month revenue reached $65.18B, driven largely by strong demand for its GLP-1 receptor agonist drugs.
Eli Lilly Revenue
Eli Lilly Annual Revenue (2005–2025)
Annual Revenue (USD Billions)
Eli Lilly Annual Revenue
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | $65.18B | $20.14B | +44.70% |
| Dec 31, 2024 | $45.04B | $10.92B | +32.00% |
| Dec 31, 2023 | $34.12B | $5.58B | +19.56% |
| Dec 31, 2022 | $28.54B | $223.00M | +0.79% |
| Dec 31, 2021 | $28.32B | $3.78B | +15.40% |
| Dec 31, 2020 | $24.54B | $2.22B | +9.95% |
| Dec 31, 2019 | $22.32B | $826.20M | +3.84% |
| Dec 31, 2018 | $21.49B | $1.52B | +7.61% |
| Dec 31, 2017 | $19.97B | -$1.25B | -5.88% |
| Dec 31, 2016 | $21.22B | $1.26B | +6.33% |